US FDA approves Pfizer's Inlyta for kidney cancer

WASHINGTON (Reuters) - Pfizer's Inlyta drug for patients with advanced kidney cancer won approval from U.S. regulators, boosting the company's efforts to offset plunging Lipitor sales. The Food and Drug Administration on Friday said the dr...